These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 23867315)
1. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315 [TBL] [Abstract][Full Text] [Related]
2. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782 [TBL] [Abstract][Full Text] [Related]
3. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Castleton A; Dey A; Beaton B; Patel B; Aucher A; Davis DM; Fielding AK Blood; 2014 Feb; 123(9):1327-35. PubMed ID: 24345754 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299 [TBL] [Abstract][Full Text] [Related]
5. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Liu C; Russell SJ; Peng KW Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340 [TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma. Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248 [TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of oncolytic measles virus: promises and challenges. Galanis E Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957 [TBL] [Abstract][Full Text] [Related]
11. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration. Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373 [TBL] [Abstract][Full Text] [Related]
12. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. Shimizu Y; Gumin J; Gao F; Hossain A; Shpall EJ; Kondo A; Parker Kerrigan BC; Yang J; Ledbetter D; Fueyo J; Gomez-Manzano C; Lang FF J Neurosurg; 2022 Mar; 136(3):757-767. PubMed ID: 34450587 [TBL] [Abstract][Full Text] [Related]
13. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus. Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013 [TBL] [Abstract][Full Text] [Related]
14. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845 [TBL] [Abstract][Full Text] [Related]
15. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199 [TBL] [Abstract][Full Text] [Related]
16. Combination of Oncolytic Measles Virus and Ursolic Acid Synergistically Induces Oncolysis of Hepatocellular Carcinoma Cells. Liu CH; Tai CJ; Kuo YT; Chang SS; Lin LT Viruses; 2023 May; 15(6):. PubMed ID: 37376594 [TBL] [Abstract][Full Text] [Related]
17. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278 [TBL] [Abstract][Full Text] [Related]
18. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Mader EK; Butler G; Dowdy SC; Mariani A; Knutson KL; Federspiel MJ; Russell SJ; Galanis E; Dietz AB; Peng KW J Transl Med; 2013 Jan; 11():20. PubMed ID: 23347343 [TBL] [Abstract][Full Text] [Related]
19. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779 [TBL] [Abstract][Full Text] [Related]
20. Chemokine CCL15 Mediates Migration of Human Bone Marrow-Derived Mesenchymal Stem Cells Toward Hepatocellular Carcinoma. Gao Y; Zhou Z; Lu S; Huang X; Zhang C; Jiang R; Yao A; Sun B; Wang X Stem Cells; 2016 Apr; 34(4):1112-22. PubMed ID: 26763650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]